Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glioma
is the most common form of malignant intracranial tumors.
Cyclin-dependent kinase-like 2
(
CDKL2
) was observed in various regions of the brain, but the specific role of
CDKL2
in
glioma
has not been reported yet. In the present study, the expression of
CDKL2
mRNA was detected by real-time QPCR in freshly collected
glioma
and para-carcinoma tissues, and we collected genomic and clinical data from The Cancer Genome Atlas to determine mRNA expression levels of
CDKL2
in the normal brain and
glioma
samples. Moreover, western blot assay and immunohistochemistry experiments were implemented to identify
CDKL2
protein expression, and clinical pathology characteristics from 151
glioma
cases and thirty-four para-carcinoma tissues were also examined. The relationship between the levels of
CDKL2
expression and clinical data was analyzed. Low mRNA and protein expression of
CDKL2
was observed in
glioma
tissues compared to non-cancerous tissues. In addition, low levels of
CDKL2
correlated with Astrocytic type, higher clinical WHO grade, and higher Ki-67 expression in
glioma
. Low mRNA and protein expression of
CDKL2
in
glioma
predicted an observably shorter overall survival time than high expression. However, as revealed by multivariate analysis,
CDKL2
protein expression was not an independent prognostic biomarker for the survival of patients with
glioma
. Our study firstly determined that low levels of
CDKL2
expression are associated with poor clinical diagnosis. Thus,
CDKL2
may serve as a prognostic factor of
glioma
.
...
PMID:Decreased CDKL2 expression is correlated with the progression and poor prognosis of glioma. 3217 42
